Zacks Investment Research cut shares of Cardica Inc. (NASDAQ:DXTR) from a hold rating to a sell rating in a report issued on Tuesday.

According to Zacks, “Dextera Surgical Inc. designs and manufactures proprietary stapling devices for surgical procedures. The company’s product consists of MicroCutter 5/80 use for transection and resection in urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the intestine and the transection of the appendix. Dextera Surgical Inc., formerly known as Cardica Inc., is headquartered in Redwood City, California. “

Cardica (NASDAQ:DXTR) opened at 1.97 on Tuesday. Cardica has a 12 month low of $1.10 and a 12 month high of $4.30. The firm’s market cap is $17.53 million. The firm’s 50-day moving average price is $1.95 and its 200-day moving average price is $2.50.

Cardica (NASDAQ:DXTR) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.01. Equities research analysts predict that Cardica will post ($1.53) earnings per share for the current year.

Cardica Company Profile

Dextera Surgical Inc, formerly Cardica, Inc, is focused on the commercialization and development of microcutter product line intended for use by surgeons. The Company is engaged in commercializing and developing MicroCutter XCHANGE 30 based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

5 Day Chart for NASDAQ:DXTR

Receive News & Stock Ratings for Cardica Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardica Inc. and related stocks with our FREE daily email newsletter.